文献速递肿瘤 PET/CT

18F-FAPI-04 PET/CT在不可切除肝细胞癌中的诊断价值:与18F-FDG PET/CT的头对头比较

The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-22

本研究回顾性纳入85例不可切除肝细胞癌患者,比较18F-FAPI-04与18F-FDG PET/CT对肝内及肝外病灶的检测能力。18F-FAPI-04在肝内病灶检出敏感性、摄取值及腹膜转移检出方面优于18F-FDG,但18F-FDG在移植受者肝内病灶、门静脉癌栓、淋巴结及肺转移检出上更高。两种示踪剂合理选择可能提高临床分期准确性。

要点

  • 基于患者的分析中,18F-FAPI-04肝内病灶检出敏感性98.8% vs 18F-FDG 85.9%(P=0.003)。
  • 基于病灶的分析中,18F-FAPI-04敏感性89.5% vs 18F-FDG 57.1%(P<0.001),但低于增强CT/MRI的96.2%。
  • 器官移植受者中18F-FDG肝内病灶敏感性87.5% vs 18F-FAPI-04 37.5%(P=0.002)。

核心结论

  • 18F-FAPI-04在不可切除肝细胞癌患者中表现出显著诊断优势,尤其在肝内病灶和腹膜转移检测方面,且对比度优于18F-FDG。
  • 在器官移植受者中,18F-FDG对肝内病灶检测的敏感性可能高于18F-FAPI-04。
  • 18F-FDG在识别门静脉癌栓方面优于18F-FAPI-04。
  • 合理选择这两种示踪剂可能提高临床分期的准确性。

研究设计与样本

  • 回顾性纳入接受配对18F-FDG和18F-FAPI-04 PET/CT检查用于治疗前分期或治疗后再分期的不可切除肝细胞癌患者。
  • 共纳入85例患者,平均年龄53.9±10.0岁。
  • 比较两种示踪剂检测肝内和肝外病灶的能力,包括敏感性、最大标准化摄取值(SUVmax)和肿瘤/本底比值(TBR)。

主要发现

  • 基于患者的分析中,18F-FAPI-04肝内病灶检出敏感性98.8% vs 18F-FDG 85.9%(P=0.003),中位最大SUVmax 9.1 vs 7.6(P=0.028)。
  • 增强CT/MRI敏感性96.5%,与18F-FAPI-04 PET相当,优于18F-FDG PET的85.9%(P=0.004)。
  • 基于病灶的分析中,18F-FAPI-04敏感性89.5% vs 18F-FDG 57.1%(P<0.001),肝内病灶中位SUVmax 6.5 vs 3.7(P<0.001),中位TBR 3.4 vs 1.7(P<0.001),但敏感性低于增强CT/MRI的96.2%(P<0.001)。
  • 器官移植受者中,18F-FDG肝内病灶检出敏感性87.5% vs 18F-FAPI-04 37.5%(P=0.002)。
  • 18F-FDG对门静脉癌栓检出率95.7% vs 18F-FAPI-04 43.5%(P=0.002),淋巴结转移95.7% vs 82.8%(P=0.004),肺转移69.3% vs 58.4%(P=0.007);18F-FAPI-04对腹膜转移检出率100% vs 18F-FDG 69.6%(P=0.016)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSES: This study aimed to evaluate the diagnostic value of 18F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma(uHCC) and with a comparative analysis against 18F-FDG PET/CT. METHODS: Patients with uHCC who underwent paired 18F-FDG and 18F-FAPI-04 PET/CT for pre-treatment staging or post-treatment restaging were retrospectively included. The two tracers were compared in terms of their ability to detect intrahepatic and extrahepatic lesions, including sensitivity, maximum standardized uptake value (SUVmax), and tumour-to-background ratio (TBR). RESULTS: Eighty-five patients (mean age: 53.9 ± 10.0 years) were included. In patient-based analysis, 18F-FAPI-04 showed higher intrahepatic lesion detection sensitivity (98.8% vs. 85.9%, P = 0.003) and lesion uptake than 18F-FDG (median maximum SUVmax:9.1 vs. 7.6, P = 0.028). Contrast enhanced CT/MRI(CECT/MR) demonstrated comparable sensitivity to 18F-FAPI-04 PET and superior to 18F-FDG PET (96.5% vs. 85.9%, P = 0.004). In lesion-based analysis, 18F-FAPI-04 demonstrated significantly higher sensitivity (89.5% vs. 57.1%, P < 0.001), intrahepatic lesion SUVmax, (median:6.5 vs. 3.7, P < 0.001) and TBR (median:3.4 vs. 1.7, P < 0.001) than 18F-FDG, but lower sensitivity than CECT/MR (89.5% vs. 96.2%, P < 0.001). Among organ transplant recipients, 18F-FDG showed superior sensitivity to 18F-FAPI-04 for detecting intrahepatic lesions (87.5% vs. 37.5%, P = 0.002). 18F-FDG had a higher detection rate of portal vein tumour thrombosis (PVTT) (95.7% vs. 43.5%, P = 0.002), lymph node metastasis (95.7% vs. 82.8%, P = 0.004), and lung metastasis (69.3% vs. 58.4%, P = 0.007).18F-FAPI-04 was significantly better than 18F-FDG in detecting peritoneal metastasis (100% vs. 69.6%, P = 0.016). According to 18F-FAPI-04 PET/CT, Barcelona Clinic Liver Cancer (BCLC) and China Liver Cancer (CNLC) staging were changed in 16 (18.8%) and 22 (25.9%) patients, respectively. CONCLUSIONS: 18F-FAPI-04 exhibits significant diagnostic advantages in uHCC patients, particularly in the detection of intrahepatic lesions, peritoneal metastases, and better contrast compared with 18F-FDG. Among organ transplant recipients,18F-FDG may offer higher sensitivity than 18F-FAPI-04 for intrahepatic lesion detection. 18F-FDG outperforms 18F-FAPI-04 in identifying PVTT. The rational selection of these two tracers may improve the accuracy of clinical staging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gong H, Cheng Y, Li Q, et al. The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40982020. doi:10.1007/s00259-025-07548-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。